Ultragenyx Pharmaceutical Inc.
A biopharmaceutical company that develops and sells treatments for rare and ultra-rare genetic diseases, many of which had no approved therapy before. Its marketed medicines include CRYSVITA for a bone disorder called X-linked hypophosphatemia and MEPSEVII for a lysosomal storage disease. Founded in 2010 by pediatric geneticist Emil Kakkis, the company's name blends "ultra" (for ultra-rare diseases) with "genyx" (for genetics), and it trades on the stock market under the ticker symbol RARE.
Granted 649.0K · Bought 12.5K · Sold 713.2K
Bought 175.0K
Sold 488.8K
Granted 276.7K · Bought 1.5K · Sold 139.4K
Granted 175.5K · Sold 9.5K
Granted 81.1K · Bought 5.0K · Sold 87.3K
Granted 190.7K · Sold 49.6K
Granted 160.7K · Sold 52.1K
Granted 102.2K · Sold 18.8K
Granted 156.2K · Sold 50.5K
Granted 236.8K · Bought 4.5K · Sold 222.6K
Granted 244.6K · Sold 147.4K
Granted 109.9K · Sold 37.8K
Granted 79.5K · Sold 12.8K
Granted 102.6K · Sold 51.1K
Granted 40.4K
Granted 40.4K
Granted 38.6K
Granted 65.4K · Bought 5.0K · Sold 33.4K
Granted 31.1K
Granted 33.7K · Sold 5.7K
Granted 25.8K
Granted 29.9K · Sold 8.8K
Granted 20.0K
Granted 17.7K
Granted 43.9K · Sold 23.7K
Granted 37.3K · Sold 34.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kakkis Emil DPresident & CEO, Director · 108 transactions | — | 4.85M | 649.0K | 12.5K | 713.2K |
| FMR LLCSee Remark 1. · 4 transactions | — | 4.72Mas of Aug 2014 | — | 175.0K | — |
| Bonderman David +2 co-filersFormer 10% Owner (2)(3)(4)(5) · 2 transactions | — | 2.60Mas of Jul 2014 | — | — | 488.8K |
| Kassberg Thomas RichardCBO & EVP · 65 transactions | — | 265.2Kas of Mar 2025 | 276.7K | 1.5K | 139.4K |
| Huang Dennis KarlSee Remarks · 45 transactions | — | 147.8K | 175.5K | — | 9.5K |
| Aliski WilliamDirector · 34 transactions | — | 137.2Kas of Jun 2021 | 81.1K | 5.0K | 87.3K |
| Pinion John RichardSee Remarks · 49 transactions | — | 133.1K | 190.7K | — | 49.6K |
| Harris ErikEVP & Chief Commercial Officer · 40 transactions | — | 118.4K | 160.7K | — | 52.1K |
| Crombez EricEVP and Chief Medical Officer · 14 transactions | — | 111.2K | 102.2K | — | 18.8K |
| Horn HowardChief Financial Officer · 17 transactions | — | 105.7K | 156.2K | — | 50.5K |
| Sharp ShaliniEVP, Finance · 93 transactions | — | 97.8Kas of Oct 2020 | 236.8K | 4.5K | 222.6K |
| Parschauer Karah HerdmanEVP and Chief Legal Officer · 72 transactions | — | 94.5K | 244.6K | — | 147.4K |
| Huizenga Theodore AlanSVP, Chief Accounting Officer · 93 transactions | — | 68.9K | 109.9K | — | 37.8K |
| Dier MardiCFO & Executive Vice President · 10 transactions | — | 66.7Kas of Oct 2022 | 79.5K | — | 12.8K |
| Bedrosian Camille LEVP and Chief Medical Officer · 30 transactions | — | 46.7Kas of Mar 2023 | 102.6K | — | 51.1K |
| Narachi MichaelDirector · 11 transactions | — | 40.4K | 40.4K | — | — |
| Welch Daniel GDirector · 11 transactions | — | 40.4K | 40.4K | — | — |
| Dunsire DeborahDirector · 10 transactions | — | 38.6K | 38.6K | — | — |
| Fust Matthew KDirector · 25 transactions | — | 33.7K | 65.4K | 5.0K | 33.4K |
| Ray AmritDirector · 6 transactions | — | 31.1K | 31.1K | — | — |
| Suliman ShehnaazDirector · 9 transactions | — | 28.0K | 33.7K | — | 5.7K |
| Dallas Jayson Donald AlexanderEVP & Chief Commercial Officer · 10 transactions | — | 23.8Kas of Jun 2018 | 25.8K | — | — |
| Sanders Corazon (Corsee) D.Director · 12 transactions | — | 21.1K | 29.9K | — | 8.8K |
| Hogenhuis WladimirChief Operating Officer · 3 transactions | — | 18.7Kas of Oct 2019 | 20.0K | — | — |
| Ekman LarsDirector · 7 transactions | — | 17.7Kas of Jun 2022 | 17.7K | — | — |
| Agarwal SunilChief Medical Officer · 36 transactions | — | 9.1Kas of Aug 2016 | 43.9K | — | 23.7K |
| Siegall Clay BDirector · 11 transactions | — | 4.1Kas of Aug 2020 | 37.3K | — | 34.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -1.98M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.